Exploring GE HealthCare Techs’s Earnings Expectations – GE HealthCare Techs (NASDAQ:GEHC)
GE HealthCare Techs (NASDAQ:GEHC) will release its quarterly earnings report on Wednesday, 2026-02-04. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate GE HealthCare Techs to report an earnings per share (EPS) of $1.41.
Investors in GE HealthCare Techs are eagerly awaiting the company’s announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It’s worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Overview of Past Earnings
In the previous earnings release, the company beat EPS by $0.02, leading to a 3.08% drop in the share price the following trading session.
Here’s a look at GE HealthCare Techs’s past performance and the resulting price change:
Tracking GE HealthCare Techs’s Stock Performance
Shares of GE HealthCare Techs were trading at $80.11 as of February 02. Over the last 52-week period, shares are down 8.09%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
Analyst Insights on GE HealthCare Techs
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding GE HealthCare Techs.
A total of 7 analyst ratings have been received for GE HealthCare Techs, with the consensus rating being Buy. The average one-year price target stands at $91.14, suggesting a potential 13.77% upside.
Understanding Analyst Ratings Among Peers
In this analysis, we delve into the analyst ratings and average 1-year price targets of ResMed, DexCom and Edwards Lifesciences, three key industry players, offering insights into their relative performance expectations and market positioning.
Analysis Summary for Peers
The peer analysis summary provides a snapshot of key metrics for ResMed, DexCom and Edwards Lifesciences, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.
Key Takeaway:
In terms of consensus, GE HealthCare Techs is rated as ‘Buy’, positioning it in the middle among peers. Revenue growth for GE HealthCare Techs is at 5.78%, placing it at the bottom. Gross profit for GE HealthCare Techs is $1.99B, ranking it at the top. Return on equity for GE HealthCare Techs is 4.53%, positioning it in the middle compared to peers.
All You Need to Know About GE HealthCare Techs
GE HealthCare Techs: A Financial Overview
Market Capitalization Perspectives: The company’s market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining GE HealthCare Techs’s financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.78% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: GE HealthCare Techs’s net margin surpasses industry standards, highlighting the company’s exceptional financial performance. With an impressive 8.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GE HealthCare Techs’s ROE surpasses industry standards, highlighting the company’s exceptional financial performance. With an impressive 4.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): GE HealthCare Techs’s ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.08, caution is advised due to increased financial risk.
To track all earnings releases for GE HealthCare Techs visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
link
